<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00534677</url>
  </required_header>
  <id_info>
    <org_study_id>297-Med/ERC-04</org_study_id>
    <nct_id>NCT00534677</nct_id>
  </id_info>
  <brief_title>The Safety &amp; Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed</brief_title>
  <official_title>Efficacy And Safety Of Terlipressin Vs Octreotide As Adjuvant Therapy In Bleeding Esophageal Varices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aga Khan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aga Khan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Terlipressin and Octreotide are two common agents used as adjuvants in the management of
      variceal bleeding. Both agents have been claimed equivalent to endoscopic therapy in
      randomized studies. There are no head to head clinical trials of these two agents available
      in the literature. We aimed to compare the efficacy and safety of Terlipressin and Octreotide
      in combination with Endoscopic Variceal band Ligation (EVL)in patients presenting with
      Esophageal Variceal Bleed (EVB).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effectiveness of combining Endoscopic treatment with Octreotide or Terlipressin has not
      been prospectively studied in esophageal variceal hemorrhage (EVH).

      This prospective, randomized clinical trial will help us in better patient management more
      efficiently and cost effectively.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety &amp; Efficacy</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">320</enrollment>
  <condition>Portal Hypertension</condition>
  <condition>Cirrhosis</condition>
  <condition>Hematemesis</condition>
  <condition>Melena</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin</intervention_name>
    <description>2 mg stat &amp; then 1 mg q6h iv and Placebo of Octreotide</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Novapresin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octreotide</intervention_name>
    <description>Octreotide 50mcg/hr infusion &amp; a placebo of Terlipressin</description>
    <arm_group_label>B</arm_group_label>
    <other_name>sandostatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All cirrhotic patients with upper GI bleed secondary to esophageal varices of 18 years
             or more of age

        Exclusion Criteria:

          -  Ulcerative esophagitis,

          -  Mallory Weiss tear,

          -  Bleeding gastric or duodenal ulcers,

          -  Bleeding from gastric varices or portal hypertensive gastropathy and

          -  Upper GI bleed as a result of thrombocytopenia or bleeding diathesis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahab Abid, FCPS, FACG</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Aga Khan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wasim Jafri, FRCP, FACG</last_name>
    <role>Study Director</role>
    <affiliation>The Aga Khan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Saeed S Hamid, FRCP, FACG</last_name>
    <role>Study Director</role>
    <affiliation>The Aga Khan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Salih Mohammad, FCPS; MACG</last_name>
    <role>Study Director</role>
    <affiliation>The Aga Khan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Aga Khan University Hospital</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>74800</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2007</study_first_submitted>
  <study_first_submitted_qc>September 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2007</study_first_posted>
  <last_update_submitted>December 4, 2007</last_update_submitted>
  <last_update_submitted_qc>December 4, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2007</last_update_posted>
  <responsible_party>
    <name_title>Dr. Shahab Abid</name_title>
    <organization>The Aga Khan University</organization>
  </responsible_party>
  <keyword>Variceal bleed</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Vasoactive agents</keyword>
  <keyword>Terlipressin</keyword>
  <keyword>Octreotide</keyword>
  <keyword>Safety &amp; Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hematemesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
    <mesh_term>Terlipressin</mesh_term>
    <mesh_term>Lypressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

